HD-OPM Archive
Topics › Insulin resistance & diabetes

Scripps team designs PPAR-gamma diabetes drugs with fewer side effects than glitazones

Louis Nervegna · Apr 11, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
Insulin resistance & diabetes
AI summary & key facts

News of a Nature Communications study in which scientists designed PPAR-gamma modulators that reprogram insulin-resistant cells in mouse and human fat cells, aiming to avoid the side effects of Avandia and Actos.

Scientists at the Scripps Institute designed a new class of PPAR-gamma activating diabetes drugs that reprogram insulin-resistant cells into a healthier state— with far fewer side effects than older PPAR-gamma medications like Avandia (rosiglitazone) and Actos (pioglitazone)

How they work:

The older thiazolidinedione class of drugs (“glitazones”) can raise the risk for fluid retention, weight gain, bone loss, and heart failure.


Note that the PPAR-gamma pathway can be activated NATURALLY with linoleic acid, the primary omega 6 fat found in nuts and seeds:

↪ Omega-6 linoleic acid improves insulin sensitivity by activating PPAR-gamma

↪ Why omega-6 lowers diabetes risk: 43% lower risk in top vs bottom blood level quintile

facebook.com/share/v/1FVcgE9tVo

↪ Linoleic acid activates PPAR-gamma like pioglitazone, which may reverse plaque

PPAR-gamma activation appears to be the primary mechanism by which omega 6 fats in nuts and seeds improve glycemic control and insulin sensitivity, as demonstrated (in aggregate) in over 100 randomized trials in humans:

↪ 100+ trials: polyunsaturated fat improves glucose and insulin markers, saturated doesn't

↪ Meta-analysis of 102 feeding trials: PUFA gives the best glucose-insulin benefits

Nuts are life extension drugs:

↪ Nut eating >3 times a week tied to 39% lower all-cause mortality in PREDIMED

————-

Quoted from the article:

The [newly developed] compounds target a master regulator of fat cell and insulin metabolism called PPAR gamma. The protein plays a role in diabetes, inflammation, cancers, obesity, heart disease and osteoporosis, making it a sought-after but complex medicinal target.

Short for peroxisome proliferator-activated receptor gamma, the PPAR gamma protein is a type of nuclear receptor, meaning it binds to the cell's DNA, and can switch clusters of genes on and off.

Type 2 diabetes patients need better options, Griffin said. Uncontrolled, the condition can lead to heart disease, nerve and blood vessel damage, cognitive decline, vision problems and more. The front-line drug for type 2 diabetes, metformin, doesn't adequately improve insulin sensitivity, especially for high-risk patients with chronic kidney disease, he said. Newer diabetes drugs also carry risks for kidney disease patients, he said.

"PPAR gamma has been a notoriously difficult target, but it remains an essential one for helping patients who still lack safe, effective options," Griffin said. "What this study shows is that with the right tools and careful design, we can finally begin to overcome those barriers."

Developing medications that target PPAR gamma has been challenging, because of the multifaceted role it plays in biology. Several diabetes drugs known as glitazones, including Actos and Avandia, robustly improve insulin sensitivity by targeting PPAR gamma. However, they are also associated with serious side effects affecting the heart, bones, and, in some cases, cancer risk.

The U.S. Food and Drug Administration mandates a boxed warning for all glitazones, highlighting their potential to cause or exacerbate congestive heart failure.

The Griffin laboratory has spent more than 15 years developing alternative compounds that fine-tune PPAR gamma activity. The new approach should allow researchers to more accurately predict therapeutic outcomes based on compound design before drugs move into later stages of testing, the scientists said.

#linoleicacidHD #ppargammaHD #omega6HD #nutsHD #seedsHD #seedoilsHD #pioglitazoneHD #diabetesHD #insulinresistanceHD #thiazolidinedionesHD #rosiglitazoneHD

phys.orgGroup potential diabetes drugs sideUsing a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have designed a group of potential diabetes drugs that reprogram insulin-resistant cells into a healthier state while limiting side effect risks of older medications.phys.org

Research cited

← newer: Omega-6 fats activate PPAR-gamma, an insulin-sensitizing patolder: Vitamin C pharmacokinetics: Levine's PNAS study shows absorp →